MediciNova, Inc. (NasdaqGM: MNOV)
Health Care · Biotechnology · US
$1.61
-9.55% today · +39.1% 1Y
MediciNova, Inc. (NasdaqGM: MNOV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $87.61M and employs 6 people.
Over the last twelve months the share price has gained 39.1%, trading between 1.17 and 3.90.
Tweenvest scores MediciNova, Inc. across four factors: quality 40/100, value 67/100. Its strongest factor is value.
MNOV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $87.61M
- Revenue (TTM)
- $920.48K
- P/E
- —
- EPS
- -0.22
- Dividend yield
- —
- Beta (5Y)
- 0.61
- 52-week high
- $3.90
- 52-week low
- $1.17
- Avg volume (3M)
- —
- Shares outstanding
- 49.22M
- Employees
- 6
- Next earnings
- —
About MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
- ISIN
- US58468P2065
- Founded
- 2000
- Listed since
- Dec 8, 2006
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BIONET Therapeutics Corp.TPEX: 7808 | $89.00M | NT$40.50 | +5.19% |
| ImmuCell CorporationNasdaqCM: ICCC | $88.55M | $9.69 | -0.62% |
| AnGes, Inc.TSE: 4563 | $88.51M | ¥35.00 | -2.78% |
| ViGenCell Inc.KOSDAQ: A308080 | $88.44M | ₩5,810.00 | +1.57% |
| Conexeu Sciences Inc.NasdaqCM: CNXU | $87.44M | $3.64 | +17.42% |
| 3D Medicines Inc.SEHK: 1244 | $87.44M | HK$2.79 | +4.30% |
| Cardiff Oncology, Inc.NasdaqCM: CRDF | $87.13M | $1.09 | -2.68% |
| ReproCELL IncorporatedTSE: 4978 | $86.89M | ¥132.00 | -6.38% |
Figures last refreshed Oct 4, 2026.